Roche Aktie

356,60 EUR -0,40 EUR -0,11 %

12:58:40

L&S

334,20 CHF +4,20 CHF +1,27 %

19.12.2025

SWX

Roche jetzt ohne Ordergebühren (zzgl. Spreads) handeln beim ‘Kostensieger’ finanzen.net zero (Stiftung Warentest 12/2025)

Jetzt loslegen

Direkt handeln

Bei einem anderen Broker handeln

Marktkap.282,11 Mrd. EUR

KGV26,06Div. Rendite3,58%

WKN851311

ISINCH0012032113

SymbolRHHBF

Roche Aktien News

Sortieren:Datum Meistgelesen

08.08.23PR NewswireNew opportunities and persistent challenges revealed as organisations attempt more data-driven approaches to healthcare, says new report from Harvard Business Review Analytic Services

03.08.23PR NewswireRoche expands long-term alliance with Sysmex

27.07.23GlobeNewswire[Ad hoc-Mitteilung gemäss Art. 53 KR] Roche verzeichnet starkes Wachstum im Basisgeschäft beider Divisionen; Konzernverkäufe und -gewinn widerspiegeln rückläufige Nachfrage nach COVID-19-Produkten

27.07.23GlobeNewswire[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong growth in both divisions’ base business; Group sales and profit reflect declining demand for COVID-19 products

24.07.23GlobeNewswireRoche enters partnership with Alnylam to co-develop and co-commercialise RNAi therapeutic zilebesiran to treat hypertension in patients with high cardiovascular risk

21.07.23GlobeNewswireCHMP recommends Roche’s Evrysdi for babies under two months old with spinal muscular atrophy (SMA)

20.07.23GlobeNewswireNew clinical and real-world data for Roche’s Vabysmo at ASRS reveal improved outcomes for people with two leading causes of vision loss

19.07.23PR NewswireRoche to showcase next-generation diagnostic solutions at the American Association of Clinical Chemistry 2023 Clinical Lab Expo

13.07.23GlobeNewswirePositive Phase III results for Roche’s OCREVUS (ocrelizumab) twice a year, 10-minute subcutaneous injection in patients with multiple sclerosis

11.07.23GlobeNewswireEuropean Commission approves Roche’s fixed-duration Columvi (glofitamab) for people with relapsed or refractory diffuse large B-cell lymphoma

30.06.23GlobeNewswireFour-year follow up data for Roche’s Evrysdi show continued increase in number of children with a severe form of spinal muscular atrophy (SMA) able to sit, stand and walk

27.06.23PR NewswireRoche receives FDA clearance for additional Alzheimer's disease Cerebrospinal Fluid (CSF) assays, supporting timely diagnosis and treatment decision-making

16.06.23GlobeNewswireFDA approves Roche’s Columvi, the first and only bispecific antibody with a fixed-duration treatment for people with relapsed or refractory diffuse large B-cell lymphoma

13.06.23GlobeNewswireRoche awarded WHO prequalification for the cobas® HPV test, increasing access to cervical cancer screening tools in low and lower-middle income countries

09.06.23GlobeNewswireNew data show Roche’s subcutaneously administered crovalimab achieved disease control and was well-tolerated in people with paroxysmal nocturnal haemoglobinuria (PNH)

08.06.23PR NewswireDevelopment in Alzheimer's disease diagnosis in Canada: New tests help patients and caregivers make timely decisions

22.05.23PR NewswireRoche introduces navify® Sample Tracking for labs to track patient test samples before even reaching lab premises

17.05.23GlobeNewswireRoche’s BTK inhibitor fenebrutinib significantly reduced brain lesions in people with relapsing forms of multiple sclerosis

17.05.23PR NewswireRoche showcases commitment to advancing innovative diagnostic solutions at WorldLab-EuroMedLab

09.05.23GlobeNewswireFDA accepts application for Roche’s Vabysmo for the treatment of retinal vein occlusion (RVO)

04.05.23GlobeNewswireRoche launches Institute of Human Biology to accelerate breakthroughs in R&D by unlocking the potential of human model systems

26.04.23GlobeNewswireCHMP recommends EU approval of Roche’s fixed-duration Columvi (glofitamab) for people with relapsed or refractory diffuse large B-cell lymphoma

26.04.23MyDividendsRoche bestätigt Ausblick und strebt Dividendenerhöhung an

26.04.23GlobeNewswire[Ad-hoc-Mitteilung gemäss Art. 53 LR] Roche erzielt im ersten Quartal ein starkes Verkaufswachstum im Basisgeschäft beider Divisionen; Rückgang der Konzernverkäufe aufgrund der erwartungsgemäss gering

26.04.23GlobeNewswire[Ad hoc announcement pursuant to Art. 53 LR] Roche reports strong sales growth in base business of both divisions in the first quarter; Group sales decline due to expected drop in demand for COVID-19

25.04.23GlobeNewswireNew Vabysmo data suggest greater retinal drying versus aflibercept in nAMD and DME

19.04.23GlobeNewswire[Ad hoc announcement pursuant to Art. 53 LR] FDA approves Roche’s Polivy in combination with R-CHP for people with certain types of previously untreated diffuse large B-cell lymphoma

16.04.23GlobeNewswireRoche’s Tecentriq plus Avastin reduced the risk of cancer returning in people with certain types of adjuvant liver cancer in a Phase III study

13.04.23GlobeNewswireRoche data highlights strength of ophthalmology portfolio and commitment to advancing eye care at ARVO 2023

11.04.23PR NewswireRoche introduces navify® Algorithm Suite, a digital library of medical algorithms that enhances clinical decision-making to optimise patient care

22.03.23GlobeNewswireRoche announces collaboration with Lilly to enhance early diagnosis of Alzheimer's disease

20.03.23GlobeNewswireNew four year data for Roche’s Evrysdi reinforce long-term efficacy and safety profile in some of the most severely affected people with types 2 and 3 spinal muscular atrophy (SMA)

14.03.23GlobeNewswireRoche Generalversammlung 2023

14.03.23GlobeNewswireRoche Annual General Meeting 2023

10.03.23GlobeNewswireFDA Advisory Committee votes in favour of the clinical benefit of Roche’s Polivy combination for people with previously untreated diffuse large B-cell lymphoma

06.03.23PR NewswireRoche receives FDA approval of label expansion for VENTANA PD-L1 (SP263) Assay to identify patients with locally advanced and metastatic non-small cell lung cancer eligible for Libtayo

Roche News

Roche News: auf dieser Seite finden Sie alle Roche News und Nachrichten zur Roche Aktie. Dies beinhaltet die Agentur-Feeds auf finanzen.net, aber auch Roche News auf einer Vielzahl externer Seiten. Externe Links sind am entsprechenden Link-Symbol zu erkennen. Um Roche News auf externen Seiten zu lesen, folgen Sie einfach dem entsprechenden Link.